Dexeus Mujer actively participates in the 39th edition of the ESHRE

Dexeus Mujer participa activamente en la 39ª edición de la ESHRE

Dexeus Mujer actively participates in the 39th edition of the ESHRE

The group presents the results of two pioneering clinical trials:
T-TRANSPORT and DUO STIM-FRESH, aimed at improving reproductive outcomes in patients who respond poorly to ovarian stimulation

Barcelona, 20 June 2023.- As in every edition, the team of the Dexeus Mujer’s, Reproduction Service, Department of Obstetrics, Gynaecology and Reproduction of Dexeus University Hospital, is actively participating in the 39th Congress of the European Society of Human Reproduction and Embriology (ESHRE), which is being held this month, from 25-28 June in Copenhagen.

Equipo Dexeus Mujer en la 39ª edición de la ESHRE

This year we are presenting the results of two pioneering randomised clinical trials: TRANSPORT and DUO STIM-FRESH, focused on patients with a low response to ovarian stimulation treatments in order to improve their reproductive outcomes in IVF/ICSI:

● The T-TRANSPORT. Transdermal testosterone treatment for poor ovarian responders
This is the first multicentre, multinational, Europe-wide study to address the efficacy of androgen use in infertile women, a topic that has been under study for more than 20 years. The trial started in 2015 and is currently in phase III. It involves 10 centres in 4 European countries (Belgium, Switzerland, Denmark and Spain). It was conducted on a sample of 300 patients.

● DUO STIM-FRESH. Double vs. single stimulation in young poor prognosis patients followed by a fresh embryo transfer
This trial investigates the results of an innovative ovarian stimulation strategy (in the follicular and luteal phase), in the same cycle, in young patients (<40 years) with a poor prognosis, who undergo a fresh embryo transfer. The aim is to check whether it can favour the obtaining of a greater number of oocytes in less time. It has been carried out on a sample of 112 patients.

Another oral communication that we present is a large study that analyses the clinical outcomes of reproductive patients with adenomyosis, a chronic pathology that can compromise fertility:

Clinical outcomes in women with adenomyosis undergoing frozen embryo transfer (FET)
It analyses the reproductive outcomes in 140 women diagnosed with adenomyosis undergoing a first cycle of cryoembryo transfer. The study was carried out on a sample of 3500 patients. This pathology is associated with a higher number of miscarriages and complications during pregnancy.

In addition, our team presents a communication that has been selected for oral discussion and four studies in poster format, which provide answers to questions currently the subject of great interest or debate in clinical practice. Below are the issues they address:


Monday 26 June
Session 22: “New Concepts: Poor Responders”
15:30 – 15:45 Transdermal testosterone prior to ovarian stimulation for in vitro fertilization in women with poor ovarian response. A multicenter multinational double-blind placebo-controlled randomized trial (The T-TRANSPORT). Nikolaos P. Polyzos
16:15 – 16:30 Double vs. single stimulation in young poor prognosis patients followed by a fresh embryo transfer: a randomized controlled trial (DUO STIM). Annalisa Racca

Wednesday 28 June
Session 81: “Management of adenomyosis: current strategies and future perspectives”
10:45 – 11:00 Presence of adenomyosis impairs clinical outcomes in women undergoing frozen embryo transfer. Noémie Sachs Guedj


Considering patients’ weight in 3 different trigger strategies.
Can Body Mass Index (BMI) influence the process of oocyte maturation? Valeria Donno
+ 5000 consecutive cycles


The influence of the ejaculatory abstinence period on semen parameters from the fisrt diagnostic sample.
Results from analysis of 14.000 samples. Piotr Sokol

“Blame it on my youth”: Is a very young donor’s age associated with different blastocyst usable rate and embryo quality? Elisabet Clua
A retrospective study of 1274 oocyte donor’s and 1738 oocyte recipients cycles

Embryo ploidy rates following progesterone-primed ovarian stimulation protocols (PPOS) or GnRH antagonist: Is there any difference? Mª del Mar Vidal
A prospective study of 44 women underwent two consecutive ovarian stimulation protocols within a period of 6 months

Economic impact of antagonist stimulation protocol vs progestin primed stimulation protocol in oocyte donor program: a retrospective study. Josep Gonzalo

¿Cómo podemos ayudarte?

Te informamos que los datos de carácter personal que proporciones rellenando el presente formulario serán tratados por Fundación Dexeus Mujer como responsable de esta web. La finalidad de la recogida y tratamiento de estos datos es contactar contigo en referencia a tu solicitud y en caso de que expresamente nos autorices enviarte información sobre actividades, promociones y/o servicios y nuestro boletín informativo periódico. La legitimación se realiza a través del consentimiento del interesado. Podrás ejercer tus derechos de acceso, rectificación, limitación y suprimir los datos ante el delegado de protección de datos en así como el derecho a presentar una reclamación ante una autoridad de control. Puedes consultar la información adicional y detallada sobre Protección de Datos en nuestra política de privacidad.

How can we help you?

We inform you that the personal data that you provide by filling in this form will be treated by Dexeus Mujer Foundation as responsible for this website. The purpose of collecting and processing this data is to contact you regarding your request and in the event that you expressly authorize us to send you information on activities, promotions and / or services and our periodic newsletter. The legitimation is carried out through the consent of the interested party. You can exercise your rights of access, rectification, limitation and delete the data before the data protection officer at as well as the right to file a claim with a control authority. You can consult the additional and detailed information on Data Protection in our privacy policy.